Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
Chonluten is a synthetic tripeptide from the Khavinson bioregulator programme, proposed to target bronchial and respiratory tissue. No human clinical trials have been conducted and it has no regulatory approval. One Western-collaborated cell study has been published, which provides a higher evidence standard than most Khavinson compounds.
Chonluten is also known by these brand and alternate names:
1 published studies: 1 human, 0 animal, 1 in-vitro, 0 reviews
Chonluten has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies, including one Western-collaborated publication.
The Western-collaborated study represents a higher standard of evidence than many Khavinson bioregulator publications, but remains a single in vitro study without clinical confirmation. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Chonluten may normalise bronchial cell function by regulating genes related to inflammation and antioxidant activity. A Western-collaborated publication using human monocytic cells reported activation of specific signalling pathways. These observations have not been confirmed through clinical studies.
Research suggests a 2022 study involving Western collaborating institutions reported signalling pathway activation in human immune cells — a somewhat stronger foundation than most Khavinson peptides. However, the primary respiratory function claims rest entirely on Russian-language publications. No human respiratory function data (spirometry, lung function tests) from controlled studies exist. No pharmacokinetic data have been published. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for Chonluten sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
Chonluten is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Gly (EDG). Its molecular weight is 319.27 Da with the molecular formula C11H17N3O8 (CAS 75007-24-8, PubChem CID 194641). Developed by Vladimir Khavinson as part of the cytomedine program, Chonluten targets bronchial and respiratory tissue. Also known as Honluten, T-34, and Peptide AC-7. No pharmacokinetic data exist. Available as a dietary supplement in Russia.
Research suggests Chonluten normalizes bronchial mucous membrane cell function by regulating genes related to inflammation, antioxidant activity, and proliferation. Identified gene expression targets include HSP70 (stress response), SOD (superoxide dismutase), c-Fos (proliferation), COX-2 (inflammation), TNF-alpha, and IL-6/IL-17 (downregulated in LPS-activated macrophages). Research suggests Chonluten activates STAT1 phosphorylation independently of receptor-associated kinases while potentially inhibiting STAT3 phosphorylation. Like other Khavinson peptides, it is hypothesized to penetrate cell nuclei and interact with DNA promoter/suppressor regions.
The strongest study is a Western-collaborated publication (Avolio et al. 2022, University of Italy + St. Petersburg) using human THP-1 monocytic cells, where Chonluten activated STAT1 phosphorylation via a possibly receptor-independent mechanism. Khavinson et al. (2012) reported normalization of antioxidant and anti-inflammatory proteins by regulating SOD, TNF-alpha, and COX-2 in murine peptic ulcer models. A systematic review (Khavinson et al. 2021) confirmed short peptides penetrate nuclei and interact with nucleosomes, histones, and DNA.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 3 vendor listings
View pricing data across vendors and countries for Chonluten
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
BPC-157 has no marketing authorisation from any major regulatory agency. No human Phase III clinical trials have been completed. The preclinical evidence base consists of over 100 animal studies, predominantly conducted at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled. No established human dosing, safety profile, or efficacy data from rigorous clinical trials exist. Products available through unregulated channels are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of this compound's evidence base.
Palovarotene (Sohonos) is approved for FOP. The Phase III MOVE trial (107 patients — representing approximately 12% of the global FOP population) initially did not meet statistical significance on its pre-specified primary analysis. However, a post-hoc re-analysis with corrected placebo data showed a 54% reduction in new heterotopic ossification volume. The approval pathway was complex given the ultra-rare nature of FOP. Palovarotene is not a peptide. Important safety considerations include premature growth plate closure in growing children, requiring monitoring. FOP has no other approved treatment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
